Peptide entry

Cagrilintide

InvestigationalPeptide

Quick facts

Category
Weight Loss
Primary goal
Fat Loss (Advanced)
Dose pattern
Weekly, titrated
Treatment style
Titrated
Status
Investigational
Vial formats
5 mg; 10 mg

Evidence / context

Evidence: Emerging. Use context is formulation-dependent.

Available vial formats

Cagrilintide

5 mg
Mix 2.0 mLConcentration 2.5 mg/mL

Titration schedule

Full ramp to 4.5 mg weekly - higher studied target

Investigational study-dose framework - not an approved prescribing schedule.

StageWeekly amountU-100 draw
Weeks 1-40.3 mg once weekly12 units
Weeks 5-80.6 mg once weekly24 units
Weeks 9-121.2 mg once weekly48 units
Weeks 13-162.4 mg once weekly96 units
Week 17+4.5 mg once weekly - maintenance180 units

Optional higher studied target; not an automatic required target.

A calculated dose above 100 units exceeds one 100-unit U-100 syringe at this concentration. Use an appropriate multi-draw plan and verify the full dose.

Escalation / hold

Escalation is not automatic. Hold the current dose longer when tolerability requires it. The 4.5 mg higher studied target is optional, not required.

Cagrilintide

10 mg
Mix 3.0 mLConcentration 3.333 mg/mL

Titration schedule

Full ramp to 4.5 mg weekly - higher studied target

Investigational study-dose framework - not an approved prescribing schedule.

StageWeekly amountU-100 draw
Weeks 1-40.3 mg once weekly9 units
Weeks 5-80.6 mg once weekly18 units
Weeks 9-121.2 mg once weekly36 units
Weeks 13-162.4 mg once weekly72 units
Week 17+4.5 mg once weekly - maintenance135 units

Optional higher studied target; not an automatic required target.

A calculated dose above 100 units exceeds one 100-unit U-100 syringe at this concentration. Use an appropriate multi-draw plan and verify the full dose.

Escalation / hold

Escalation is not automatic. Hold the current dose longer when tolerability requires it. The 4.5 mg higher studied target is optional, not required.

Reconstitution

  1. Swab vial tops with alcohol
  2. For the 5 mg vial, add 2.0 mL bacteriostatic water slowly
  3. For the 10 mg vial, add 3.0 mL bacteriostatic water slowly
  4. Swirl gently - do not shake
  5. Refrigerate 2-8 C

Study/treatment duration

The selected target continues once weekly for the remaining planning period after escalation.

Timing

Treat like a satiety-focused weekly tool. Move up slowly and hold longer if GI side effects persist. Keep meals smaller during early titration.

Support / expected effects

Side effects / tolerability

Practical tips

Storage

Refrigerate 2-8 C after mixing and follow the product-specific beyond-use window.

Notes / compatibility

Notes

  • Clinical note: use context is formulation-dependent.
  • Future finished-product formulations may differ from vial formats.
  • Keep appetite-agent stacks simple enough to interpret.

Compatibility

Keep separate from other injections. Appetite agents are easier to assess when used cleanly.

FAQ

What titration schedule is shown for Cagrilintide?

Each vial card shows the same 4.5 mg weekly - higher studied target. Investigational study-dose framework - not an approved prescribing schedule.

How does Cagrilintide titration work?

Start at 0.3 mg once weekly and follow the stages shown in the vial card. Escalation is not automatic. Hold the current dose longer when tolerability requires it. The 4.5 mg higher studied target is optional, not required.

What is the treatment-duration context for Cagrilintide?

The selected target continues once weekly for the remaining planning period after escalation.

How are doses measured in syringe units here?

Units mean U-100 insulin-syringe gradations (1 mL = 100 units), not International Units. Use the conversion table for the selected vial format and confirm syringe and vial capacity.

Calculate the exact draw for CagrilintidePreloads the relevant vial format or fixed-ratio blend cycle.
Open calculator